The dual trigger approach offers the advantage of combining both GnRH agonist and hCG, thereby reducing the OHSS risk by minimizing hCG dosage while it can also induce endogenous FSH and LH surges. The gene discussed is PLOD1; the disease is ovarian hyperstimulation syndrome.